Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
Biotech
Cell & Gene Therapy
Clinical Data
Oncology
Venture Capital
Deals
Research
Medtech
Devices
Diagnostics
AI and Machine Learning
CRO
Special Reports
Trending
Biologics
Clinical Development
Ophthalmology
Cell & Gene Therapy
Drug Development
Small Molecule Research & Development
Oncology
Fierce 50
Special Report
Awards Gala
Awards
Outsourcing Awards
Innovation Awards
Resources
Fierce Events
Industry Events
Webinars
Podcasts
Whitepapers
Survey
Events
Subscribe
Subscribe
Biotech
Cell & Gene Therapy
Clinical Data
Oncology
Venture Capital
Deals
Research
Medtech
Devices
Diagnostics
AI and Machine Learning
CRO
Special Reports
Trending
Biologics
Clinical Development
Ophthalmology
Cell & Gene Therapy
Drug Development
Small Molecule Research & Development
Oncology
Fierce 50
Special Report
Awards Gala
Awards
Outsourcing Awards
Innovation Awards
Resources
Fierce Events
Industry Events
Webinars
Podcasts
Whitepapers
Survey
Events
Subscribe
Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
GSK
Biotech
GSK continues stockpiling Wave drugs with liver-focused program
GSK is paying Wave Life Sciences $12 million upfront to take ownership of a hepatic program arising from the companies’ long-running collaboration.
James Waldron
Sep 30, 2026 9:19am
Scynexis bags $214M BARDA contract for antifungal development
Sep 28, 2026 9:29am
GSK aiming to ‘balance West and East’ since Hansoh deal success
Sep 23, 2026 5:00am
GSK doubles down on Chimagen with $750M multiple myeloma wager
Sep 15, 2026 7:15am
GSK’s ADC lays down marker for lung cancer scrap with Merck
Sep 12, 2026 7:00pm
GSK pens $1.3B Hutchmed deal for KRAS-EGFR cancer asset
Sep 3, 2026 7:45am
